Previous close | 513.70 |
Open | 518.10 |
Bid | 520.40 x 60000 |
Ask | 521.40 x 60000 |
Day's range | 518.10 - 521.30 |
52-week range | 398.00 - 557.30 |
Volume | |
Avg. volume | 81 |
Market cap | 200.169B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 36.23 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.44 (0.28%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | N/A |
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical (NASDAQ:RARE) over the use of cells taken from Lacks’ body in the 1950s, as ruled by a Maryland federal court on Monday. U.S. District Judge Deborah Boardman rejected Ultragenyx’s motion to dismiss the case, determining that the estate had plausibly claimed that Ultragenyx wrongly profited from its research using the “immortal” HeLa cell line. The HeLa cells, extracted from Lacks’ cervix without her knowle
Thermo Fisher Scientific (NYSE:TMO) has had a great run on the share market with its stock up by a significant 9.0...